InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.039 0.002 (5.41%)+
Announcement
Release
4 May 2026 9:08AM
Price at Release
$0.037
Full Release
download
Summary
Entropy Neurodynamics Limited announced a breakthrough in its Phase 2a clinical trial of TRP-8802, an oral psilocybin treatment for treatment-resistant irritable bowel syndrome (IBS). The trial achieved a 75% response rate, a significant improvement over existing therapies which typically show 17-44% response rates. The study, which involved 12 patients, linked clinical improvements to psychological flexibility and insight, supporting the gut-brain axis mechanism. The results not only enhance the development prospects of TRP-8803, an IV-infused psilocin formulation, but also position Entropy advantageously for potential partnerships, larger trials, and grant funding opportunities. IBS represents a substantial market opportunity, particularly in the US, where patients spend over $60 billion annually on treatments.
Key Points
  • Phase 2a clinical trial of TRP-8802 achieved 75% response rate
  • Clinical improvements linked to psychological flexibility and insight
  • Supports gut-brain axis mechanism of action
  • Potential for TRP-8803 development and partnerships
  • IBS market in the US exceeds $60 billion annually
  • Study involved 12 treatment-resistant IBS patients
  • Results presented at Digestive Disease Week 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.